

Formulation, Development And Evaluation Of Sedds Of Herbal Bioactive

Shailendra prasad tiwari, dr. Shailesh kumar gupta

Mansarovar Global University, Sehore, Madhya Pradesh, India

Abstract :

In order to increase *Sarcostemma acidum* extract's solubility, in vitro dissolving efficiency, and bioavailability, the current work set out to design a self-emulsifying drug delivery system (SEDDS). *Sarcostemma acidum* extract's solubility in a range of oils, surfactants, and co-surfactants was assessed. The prepared SEDDS was assessed for stability, in vitro dissolution, drug content, and emulsification time. Maximum solubility, reduced emulsification time, good stability, and enhanced in vitro release were all demonstrated by the optimized formulation. In this investigation, data was imported using pre-existing historical data. It was determined that SEDDS would be a viable oral medication delivery method for poorly water-soluble plant extract.

Keywords: SEDDS, *Sarcostemma acidum*, solubility enhancement, herbal bioactive, self-emulsifying drug delivery system.

How to cite this article: Tiwari SP, Gupta SK. Formulation, Development And Evaluation Of Sedds Of Herbal Bioactive. *Int J Drug Deliv Technol.* 2026;16(6s): 628-633; DOI: 10.25258/ijddt.16.6s.88

Introduction

Around 60% of herbal new drug candidates have less solubility, and the oral deliveries of such drugs are associated with low bioavailability. To overcome these problems, various formulation strategies are exploited including the use of surfactants, lipids, permeation enhancers, and micronization. Majority of these approaches have their limitations because of the need for specialized equipment, complicated manufacturing process, longer processing time, and regulatory complexity. Lipid-based formulation approaches, particularly the self-emulsifying drug delivery system (SEDDS), are well known for their potential as an alternative approach for delivery of hydrophobic drugs, which are associated with poor water solubility and low oral bioavailability. SEDDS is among the methods used to improve the oral bioavailability of poorly soluble drugs by presenting and maintaining the drug in a dissolved state, in small droplets of oil, all over its transit through the gastrointestinal tract (GIT).

SEDDSs are the isotropic mixtures of oil, surfactant, cosurfactant, and drug which form oil in water microemulsion. These formulations spread readily in the GIT, and the digestive motility of the stomach and intestine the agitation necessary for self-emulsification. In a good self emulsifying system, small emulsion droplets containing dissolved drug are formed on contact with the gastrointestinal fluid. The drug in the fine emulsion droplets is exposed to a large interfacial

area, thus allowing for greater diffusion through the membrane to take place.

Formulation of self emulsifying drug delivery system (SEDDS)

Solubility Profile: Solubility of *Sarcostemma acidum* extract was checked visually in distilled water, methanol, ethanol, ethyl acetate, chloroform, acetone and phosphate buffer (pH 5.4). Accurately weighed 1 gm of drug was transferred in a clean and dry test tube followed by addition of the solvents individually and shaken vigorously and the solubility of drug was checked visually.

Determination of solubility in ethyl acetate and phosphate buffer pH 5.4 mixture for determination of ratio; accurately weighed 20 mg of *Sarcostemma acidum* extract was added individually to then clean and dried volumetric flasks each of 10 ml capacity. ETHYL ACETATE and phosphate buffer pH 5.4 solvent system was added in the ratio 1:9, 2:8, 3:7, 4:6, 5:5, 6:3, 7:3, 8:2, 9:1 and the samples were shaken for 1 hour on linear motion shaker (Model no. REMI RQ 123, Spectra Whirlmatic Lab, India). The solutions were checked visually for their clarity.

Analytical Methodology: The ultraviolet absorption spectrum of a solution of *Sarcostemma acidum* extract in ethyl acetate and (8:2) mixture of ethyl acetate and Phosphate buffer pH 5.4 was obtained using UV/VIS spectrophotometer over a wavelength range of 200 to 400 nm. Maximum absorption (λ_{max}) values were

Formulation, Development And Evaluation Of Sedds Of Herbal Bioactive

determined and further used for plotting calibration curve.

Characterization of Oil, Surfactant and Co-Surfactant for Microemulsion⁸⁻⁹

Determination of Solubility in various Oil, Surfactant and Co-surfactant: Preformulation solubility analysis was done to select the vehicle in which drug is more soluble and suitable for formulation of SEDDS. The solubility of drug in various oils, surfactants and co surfactants was measured and the solvents for the study were selected based on the good solubilising capacity for drug. In present study the solubility of drug was investigated in different oils like soyabean, olive oil, Virgin coconut oil 90 etc, surfactants and co-surfactants like Tween 80, labrasol, Cremophor EL and PEG 400, Propylene glycol etc. An excess amount of drug was added into each vehicle followed by vortex mixing for 30sec (Remi mixer, Mumbai). Mixtures were shaken for 48 h at 300 C, followed by equilibrium for 24 hr. The equilibrated samples were then centrifuged at 1000 rpm for 10 min to remove the insoluble drug and clear supernatant liquid was decanted. An aliquot of the supernatant was diluted with ethyl acetate and solubility of drug was estimated by UV spectroscopy at 255 nm.

Screening of oils and surfactant: The oils and surfactants were selected on the basis of their tendency for instant emulsification and solubility in extract. The oils selected for this investigation were Virgin coconut oil, Olive oil and Soyabean oil. The surfactants selected were Tween 80, Labrasol and Cremophor EL. The oils and surfactant were mixed in a ratio of 1:1. Briefly, 150 mg of the surfactants were added to 150 mg of the oily phase. Each mixture, 100 mg, was then diluted with distilled water to 100 ml in a stoppered conical flask. Ease of emulsification was judged by the number of flask inversions required to yield homogenous emulsion. Emulsions were allowed to stand for 2hr and their % transmittance was evaluated at 638 nm by UV-Visible spectrophotometer using distilled water as a blank. Emulsions were furthermore observed visually for any turbidity or phase separation.

Preliminary screening of co-surfactants: The selected oily phase and surfactant were used for further screening of the different co- surfactants (Propylene glycol, PEG 400 and Tanscutol) for their emulsification ability. Mixtures of 200 mg of co-surfactant, 400 mg selected surfactant, and 600 mg screened oil were

prepared and evaluated in a similar fashion as described in preliminary screening of surfactants.

Formulation of Self Emulsifying Drug Delivery System⁸⁻¹⁰

Self Emulsifying Drug Delivery system of Sarcostemma acidum extract was formulated by mixing oil, surfactant and co-surfactant with varying component ratio. In all the formulation amount of Sarcostemma acidum extract was kept constant and varying ratio of oil and Surfactant and co surfactant mixture were added. The required amount of Sarcostemma acidum extract was dissolved in selected oil at room temperature by permanent agitation and then mixture of surfactant and co-surfactant were added with gentle stirring and sonication. Then an appropriate amount of water was added to the mixture drop wise with constant stirring. Micro emulsion of Sarcostemma acidum extracts was obtained spontaneously on stirring the mixture at ambient temperature. The various formulation ratios (HF1 to HF8) are given in Table 1. The process of self-emulsification was visually monitored for the rate of emulsification and for the appearance of the produced emulsions. The visual properties registered against the increment of the applied surfactant component in Ternary triangular diagrams. Plotting points of preferential combinations were selected according to calculation.

Table 1: Compositions of Sarcostemma acidum extract (SNEDDS) (1-8)

Compositions	Formulation code	Virgin coconut oil	PEG-400	Cremophore EL	Tween-80
Composition 1	HF1	35 %	35 %	30 %	-
Composition 2	HF2	25 %	50 %	25 %	-
Composition 3	HF3	20 %	60 %	20 %	-
Composition 4	HF4	25 %	25 %	50 %	-
Composition 5	HF5	35 %	35 %	-	30 %
Composition 6	HF6	25 %	50 %	-	25 %
Composition 7	HF7	15 %	60 %	-	15 %

Formulation, Development And Evaluation Of Sedds Of Herbal Bioactive

Composition 8	HF8	25 %	25 %	-	25%
---------------	-----	------	------	---	-----

Evaluation of Formulation Self Emulsifying Drug Delivery System¹⁰⁻¹⁵

Drug content: Self-emulsifying drug delivery systems formulation equivalent to 100 mg of *Sarcostemma acidum* extract was taken and dissolved in small quantity of methanol. Volume was made up to 100 ml with ethyl acetate solution (1 mg/ml). From the above stock solution, 0.2 ml (200 µg/ml) was withdrawn and diluted up to 10 ml with methanol (20 µg/ml). Samples were prepared in triplicate and absorbance measured at 255 nm using UV-visible spectrophotometer. ethyl acetate was used as a reference solution.

Self emulsification assessment: SMEDDS should form stable microemulsion instantaneously in GI fluids upon administration. Efficiency of selected combination of surfactant and co-surfactant in self microemulsification was assessed by dispersing the SMEDDS in 250 mL of water with magnetic stirring at 100 rpm to create gentle turbulence that mimic in vivo condition and assessed visually.

In-vitro dissolution studies: The quantitative in-vitro dissolution studies are carried out to assess drug release from oil phase into aqueous phase by USP type II dissolution apparatus use of 900 ml of pH 6.8 phosphate buffer solution at 75 rpm and maintain the temperature at 37°C ± 0.5°C. Aliquots of 5 ml samples were withdrawn at regular intervals of time (5, 10, 15, 30, 60 min) and volume withdrawn was replaced immediately with fresh medium. Samples taken were then analyzed by use of UV spectrophotometer at 255 nm.

Accelerated Stability Studies

The optimized formulations SEDDS were filled in the glass vial, sealed with rubber cap and crimped for storing in the stability chamber. Samples were subjected to a stability testing for six months as per ICH norms at a temperature and RH of 40°C ± 2°C/75% RH ± 5% RH respectively. The selected formulations were analyzed for the change in droplet size, zeta potential, self-emulsification capacity and drug content.

Solubility Profile

Solubility of powdered extract of *Sarcostemma acidum* in various solvent are presented is in Table.2 It can be revealed from table that *Sarcostemma acidum* is soluble in ethyl acetate, thus ethyl acetate was selected for further studies.

Table 2: Solubility Profile of *Sarcostemma acidum* extract

S. No	Solvent	Solubility
1.	Distilled Water	Sparingly Soluble
2.	Methanol	Sparingly Soluble
3.	Ethanol	Sparingly Soluble
4.	Acetone	Sparingly Soluble
5.	Chloroform	Sparingly Soluble
6.	Phosphate Buffer (5.4 pH)	Sparingly Soluble
7.	Ethyl Acetate	Soluble

Analytical Methodology UV-Visible Spectroscopy

The Lamda max (λ_{max}) of *Sarcostemma acidum* extract in ethyl acetate was found to be 255 nm.

Characterization of Oil, Surfactant and Co-Surfactant Selection of Excipients

In this study, we selected Tween 80 and Labrasol as a surfactant. Transient negative interfacial tension and fluid interfacial film are rarely achieved by the use of single surfactant; usually, addition of a co surfactant is necessary. The presence of co surfactant decreases the bending stress of interface and allows the interfacial film sufficient flexibility to take up different curvatures required to form microemulsions over a wide range of composition.

Table 3: Solubility of *Sarcostemma acidum* in Various Oil, Surfactant and Co-surfactants

S. No.	Solvent	Solubility (µg/ml) of <i>Sarcostemma acidum</i>
1.	Olive Oil	28.1
	Virgin coconut oil 90	67.4
	Soyabean Oil	34.5
2.	Tween 80	74.23
	Labrasol	76.4
	Cremophor	73.4
3.	Propylene Glycol	58.2
	PEG 400	40.9
	Transcutol	43.3

Thus, co surfactant selected for the study was PEG 400, which has an HLB value of 11-16. Surfactants and co-

Formulation, Development And Evaluation Of Sedds Of Herbal Bioactive

surfactants were selected on the basis of their emulsification efficiency and ability to solubilise *Sarcostemma acidum* extract.

Drug content

The % drug content of all SEDDS formulations was found to be within the acceptable limits of drug content test. The Assay results are shown in table.

Table 4: Drug Content of SEDD formulation with *Sarcostemma acidum* extract

S. No.	Formulation	Percentage of Drug contents (X ± SD)
1	HF1	96.4±1.7
2	HF2	98.5±0.5
3	HF3	98.7±0.7
4	HF4	96.7±96
5	HF5	96.5±0.9
6	HF6	98.3±0.8
7	HF7	98.2±1.3
8	HF8	94.3±1.8

SD = Standard deviation

Determination of self-emulsification time

Emulsification time is an important index for the assessment of the efficiency of emulsion formation. SEDDS should disperse completely and rapidly when subjected to aqueous dilution under mild agitation. Formulation should disperse quickly when subjected to aqueous dilution under gentle agitation of GIT due to peristaltic activity. The emulsification time of all formulations was reported in Table. The lowest emulsification time 58 seconds was found in HF3 formulation and highest emulsification time 158 seconds was found in HF8 formulation. After observation it was found that the HF3 formulation forms microemulsion in a short time relatively among all other formulations which indicate that the HF3 was best of all prepared formulations.

Table No.6: Self Emulsification time of SEDDS formulation

S. No.	Formulation	Self Emulsification Time
1	HF1	100 ± 1.8
2	HF2	67 ± 0.4
3	HF3	58 ± 0.6
4	HF4	110 ± 2.8
5	HF5	100± 0.7
6	HF6	97 ± 5.6
7	HF7	66 ± 1.3

8	HF8	158 ± 2.4
---	-----	-----------

In-vitro dissolution study

In-vitro dissolution study was conducted to compare the pure extract release from the developed *Sarcostemma acidum* extract SEDDS formulation. Quantitative in vitro dissolution studies are performed to assess drug-release from the oil phase to the aqueous phase by USP Type II dissolution apparatus.

The results of the in vitro dissolution studies were listed in the table and figures below. After looking at the results, it was found that, about 97.12% drug was released from *Sarcostemma acidum* SEDDS HF3 formulation within 60 minutes as compared to other formulations, i.e. HF1, HF2, HF4, HF5, HF6, HF7 and HF8, which were 68.15%, 85.10%, 58.21%, 63.15%, 79.21, 88.86% and 52.15% of the drug respectively. Thus, the drug release from *Sarcostemma acidum* SEDDS HF3 formulation was found to be significantly higher as compared to the remaining SEDDS formulation and pure extract. It could be suggested that the SEDDS HF3 formulation resulted in the spontaneous formation of a microemulsion with smaller droplet size, which allowed a faster release rate of the drug into the aqueous phase. Thus, greater availability of dissolved *Sarcostemma acidum* extract from the SEDDS HF3 formulation may lead to higher absorption and higher oral bioavailability.

The release data obtained in this study was extrapolated by zero order, first order, Higuchi, Korsmeyer-Peppas, Hixon-Crowell equations to know the mechanism of drug release from the formulation. The in vitro drug release profile of the optimized formulation HF3 was best expressed by the Higuchi equation as the plots showed the highest linearity (coefficient of determination, R² = 0.993).

The formulations showed good linearity when plotted according to Higuchi equation. It can be inferred that the release was dependent on both motility and polymer relaxation.

Table 8: In-vitro drug release profile of SEDDS formulation

Time	SEDDS Formulation							
	HF1	HF2	HF3	HF4	HF5	HF6	HF7	HF8
5	22.63	27.85	32.85	18.45	18.69	21.82	26.4	14.85
10	39.32	40.88	46.88	31.98	34.32	36.64	38.97	24.21
15	44.23	52.89	58.55	40.43	41.22	49.76	49.89	32.36
30	53.83	63.68	73.68	47.44	48.87	59.98	66.67	42.44

Formulation, Development And Evaluation Of Sedds Of Herbal Bioactive

45	62.25	74.45	90.45	52.47	57.81	69.75	77.98	46.47
60	68.15	85.10	97.12	58.21	63.15	79.21	88.86	52.15




Figure 1; Percentage drug release Study of optimized formulation

Stability Studies

Samples from stability chamber were withdrawn at regular intervals and evaluated for self emulsification efficiency, droplet size and zeta potential measurements. Results were represented in Table. There was no significant change in the droplet size, zeta potential and self-emulsification capacity. Clear dispersion with closer droplet size with initial samples indicates the stability of SMEDDS.

Table 9: Stability studies of Formulation

Formulation Code	Self emulsification time (min)	Drug contents
HF3	65 ±0.4	98.36

References

- Gursoy RN, Benita S. Self-Emulsifying Drug Delivery System (SEDDS) for Improved Oral Delivery of Lipophilic Drugs. *Biomed & Pharm* 2004; 58:173-82.
- Kaukonen AM, Boyd BJ, Porter CJ, Charman WN. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. *Pharm Res* 2004; 21:245-53.
- Kumar A, Sharma S, Kamble R. Self Emulsifying Drug Delivery System (SEDDS): Future Aspects. *Int J Pharm Pharm Sci* 2010; 2(4):7-13.
- Dabros T. Emulsification through area contraction. *J Colloids Interface Sci* 1999; 210:222-30.
- Reiss H. Entropy induced dispersion of bulk liquids. *J. Colloid Interface Sci* 1975; 53:61-70.
- Wakerly MG, Pouton CW, Meakin BJ. Evaluation of the self-emulsifying performance of a non-ionic surfactant-vegetable oil mixture. *J Pharm Pharmacol* 1997; 39:6.
- Charman WN, Stella VJ. Transport of lipophilic molecules by the intestinal lymphatic system. *Adv Drug Del Rev* 1991; 7:1-14.
- Gupta AK, Mishra DK. Preparation and evaluation of selfemulsifying drug delivery system of anti-hypersensitive drug valsartan. *Int J Pharm Life Sci* 2011;2: 633-639.
- Tejinder kaur marwaha et all., "formulation design and evaluation of anti-inflammatory activity of commiphora mukul loaded emulgel", *Journal of research and education in Indian medicine*, April-June 2014; Vol. XX (2): 75-87
- Tran, P.; Park, J.-S. Recent trends of self-emulsifying drug delivery system for enhancing the oral bioavailability of poorly water-soluble drugs. *J. Pharm. Invest.* **2021**, 51, 439– 463,
- Kabil, M. F.; Dena, A.S.A.; El-Sherbiny, I. M. Ticagrelor, in *Profiles of Drug Substances, Excipients and Related Methodology*; Elsevier, 2022; pp 91– 111.
- Khalid, K. W.; Abd Alhammad, S. N. Preparation and in-vivo Evaluation of Ticagrelor Oral Liquid Self nano-emulsion. *J. Pharm. Negat. Results* **2022**, 13 (3), 274.
- Ashfaq, M.; Shah, S.; Rasul, A.; Hanif, M.; Khan, H. U.; Khames, A.; Abdelgawad, M. A.; Ghoneim, M. M.; Ali, M. Y.; Abourehab, M. A. Enhancement of the solubility and bioavailability of pitavastatin through a self-nanoemulsifying drug delivery system (SNEDDS). *Pharmaceutics* **2022**, 14 (3), 482.
- Shafiq, S.; Shakeel, F.; Talegaonkar, S.; Ahmad, F. J.; Khar, R. K.; Ali, M. Development and bioavailability assessment of ramipril nanoemulsion formulation. *Eur. J. Pharm. Biopharm.* **2007**, 66 (2), 227– 243.
- Jianxian, C.; Saleem, K.; Ijaz, M.; Ur-Rehman, M.; Murtaza, G.; Asim, M. H. Development and in vitro evaluation of gastro-protective

Formulation, Development And Evaluation Of Sedds Of Herbal Bioactive

aceclofenac-loaded self-emulsifying drug
delivery system. Int. J.
Nanomed. **2020**, 15, 5217– 5226